Clinical Trial Update: Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating sargramostim, vaccine therapy, or combination to prevent melanoma recurrence after surgical removal; study completed with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Vaccine therapy
• sargramostim (sargramostim)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma | Phase 3 | Status: COMPLETED | Results posted: 2014-08-12